免疫チェックポイント阻害剤に関連する致命的な毒性作用

Wangら（火曜日）はこの問題を研究しました。

www.synapsesocial.com/papers/69d6cb12a0177bf533ed90bb — DOI: https://doi.org/10.1001/jamaoncol.2018.3923

Also consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma· 2017 · 2,189 citations
2. Incidence of immune checkpoint inhibitor-related colitis in solid tumor patients: A systematic review and meta-analysis· 2017 · 211 citations
3. Randomized, Double-Blind, Phase III Trial of Ipilimumab Versus Placebo in Asymptomatic or Minimally Symptomatic Patients With Metastatic Chemotherapy-Naive Castration-Resistant Prostate Cancer· 2016 · 749 citations
4. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement.· 2009 · 45,128 citations
5. Lung Adjuvant Cisplatin Evaluation: A Pooled Analysis by the LACE Collaborative Group· 2008 · 2,653 citations